Fibromuscular dysplasia surgery: Difference between revisions
| (3 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Fibromuscular dysplasia}} | {{Fibromuscular dysplasia}} | ||
{{CMG}}; {{AE}} | {{CMG}}; {{AE}}{{M.B}} | ||
==Overview== | ==Overview== | ||
| Line 7: | Line 7: | ||
==Indications== | ==Indications== | ||
There are no evidence-based guidelines and randomized, controlled trials comparing revascularization and medical therapy in patients with FMD; but revascularization is usually reserved for patients with either:<ref name="PersuGiavarini2014">{{cite journal|last1=Persu|first1=Alexandre|last2=Giavarini|first2=Alessandra|last3=Touzé|first3=Emmanuel|last4=Januszewicz|first4=Andrzej|last5=Sapoval|first5=Marc|last6=Azizi|first6=Michel|last7=Barral|first7=Xavier|last8=Jeunemaitre|first8=Xavier|last9=Morganti|first9=Alberto|last10=Plouin|first10=Pierre-François|last11=de Leeuw|first11=Peter|title=European consensus on the diagnosis and management of fibromuscular dysplasia|journal=Journal of Hypertension|volume=32|issue=7|year=2014|pages=1367–1378|issn=0263-6352|doi=10.1097/HJH.0000000000000213}}</ref> | |||
*HTN of recent onset with the goal of cure | |||
*Drug resistance or intolerance | |||
* | *[[Renal artery]] dissection | ||
* | *[[Renal artery]] [[aneurysm]] | ||
* | *Preservation of [[Kidney|renal]] function or prevent renal size reduction | ||
* | |||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
Latest revision as of 23:35, 19 August 2018
|
Fibromuscular dysplasia Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
ASA/ACCF/AHA Guideline Recommendations |
|
Management of Patients With Fibromuscular Dysplasia of the Extracranial Carotid Arteries |
|
Case Studies |
|
Fibromuscular dysplasia surgery On the Web |
|
American Roentgen Ray Society Images of Fibromuscular dysplasia surgery |
|
Risk calculators and risk factors for Fibromuscular dysplasia surgery |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mohsen Basiri M.D.
Overview
Revascularization by surgical intervention or percutaneous transluminal angioplasty (PTA) , are not the first-line treatment options for patients with FMD, however in cases of FMD-related RAS with signs of downstream reduction of renal function or in case of drug-resistant HTN vascular reconstruction should be considered.
Indications
There are no evidence-based guidelines and randomized, controlled trials comparing revascularization and medical therapy in patients with FMD; but revascularization is usually reserved for patients with either:[1]
- HTN of recent onset with the goal of cure
- Drug resistance or intolerance
- Renal artery dissection
- Renal artery aneurysm
- Preservation of renal function or prevent renal size reduction
References
- ↑ Persu, Alexandre; Giavarini, Alessandra; Touzé, Emmanuel; Januszewicz, Andrzej; Sapoval, Marc; Azizi, Michel; Barral, Xavier; Jeunemaitre, Xavier; Morganti, Alberto; Plouin, Pierre-François; de Leeuw, Peter (2014). "European consensus on the diagnosis and management of fibromuscular dysplasia". Journal of Hypertension. 32 (7): 1367–1378. doi:10.1097/HJH.0000000000000213. ISSN 0263-6352.